This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Valuation

Q: What is the Fair Price of MITRAb when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MITRAb (€2.96) is trading below our estimate of [[fair value]] (€117.89)

Is MITRAb undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MITRAb when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MITRAb (€2.96) is trading below our estimate of fair value (€117.89)

Significantly Below Fair Value: MITRAb is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MITRAb?

Key metric: As MITRAb is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MITRAb. This is calculated by dividing MITRAb's market cap by their current revenue.
What is MITRAb's PS Ratio?
PS Ratio	1.6x
Sales	€62.68m
Market Cap	€100.90m

MITRAb key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.1x
Enterprise Value/EBITDA	-11.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MITRAb's PS Ratio compare to its peers?

The above table shows the PS ratio for MITRAb vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.4x
REDX Redx Pharma	13.9x	-37.6%	UK£58.3m
EAH ECO Animal Health Group	0.5x	5.9%	UK£44.4m
ANCR Animalcare Group	2x	3.8%	UK£148.5m
APH Alliance Pharma	1.3x	5.2%	UK£243.8m
MITRAb Mithra Pharmaceuticals	1.6x	14.1%	€100.9m

Price-To-Sales vs Peers: MITRAb is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does MITRAb's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
EAH ECO Animal Health Group	0.5x	5.9%	US$56.26m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MITRAb is good value based on its Price-To-Sales Ratio (1.6x) compared to the European Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is MITRAb's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MITRAb PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MITRAb's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

3.6%

-24.5%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

-3.8%

4.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.96

2.0%

-7.1%